Yanagihara Y, Abe T, Kuroda T, Shida T
Clinical Research Center for Allergy, National Sagamihara Hospital, Kanagawa, Japan.
Arzneimittelforschung. 1988 Jan;38(1):88-92.
The effects of butyl 3'-(1H-tetrazol-5-yl)oxanilate (WP-833), a new antiallergic drug, on immunological reactions in mice and humans were studied in view of possible side effects. Hemagglutinin formation in mice immunized with sheep red blood cells was not suppressed by WP-833 administered i.p. or p.o. for 3 days either before or after immunization. In addition, the same treatments with WP-833 showed no suppression of hapten-specific immunoglobulin E (IgE) or immunoglobulin G (IgG) antibody formation in mice immunized with dinitrophenyl-conjugated ovalbumin mixed with alum. The proliferation of human peripheral blood lymphocytes induced by concanavalin A, phytohemagglutinin-P, pokeweed mitogen, protein A or Cowan I was not suppressed by WP-833. Nitroblue tetrazolium reduction test, phagocytosis and chemotaxis in human neutrophils were not inhibited by WP-833.
鉴于可能存在的副作用,研究了新型抗过敏药物3'-(1H-四氮唑-5-基)氧代苯甲酸丁酯(WP-833)对小鼠和人类免疫反应的影响。用绵羊红细胞免疫的小鼠,在免疫前或免疫后经腹腔注射或口服WP-833 3天,血凝素的形成未受抑制。此外,用与明矾混合的二硝基苯基偶联卵清蛋白免疫的小鼠,同样用WP-833处理未显示对半抗原特异性免疫球蛋白E(IgE)或免疫球蛋白G(IgG)抗体形成的抑制作用。WP-833未抑制伴刀豆球蛋白A、植物血凝素-P、商陆有丝分裂原、蛋白A或考恩I诱导的人外周血淋巴细胞增殖。WP-833未抑制人中性粒细胞的硝基蓝四氮唑还原试验、吞噬作用和趋化性。